Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were successfully weaned off other therapy.

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Tirzepatide mimics the hormones GLP-1 and GIP, which a person’s stomach produces whenever they eat. These hormones reduce appetite, which can result in weight loss. You must also follow a ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.